文献速递产科母胎医学

血管生成标志物及其纵向变化预测慢性高血压孕妇不良结局

Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-01

该回顾性研究纳入145例慢性高血压合并疑似子痫前期的孕妇,评估血清sFlt-1、PlGF及其比值对不良母胎结局的预测准确性。结果显示,sFlt-1/PlGF比值Z评分和PlGF水平Z评分预测1周内并发症的AUC分别达0.95和0.94,显著优于临床症状指标;纵向测量比值变化的AUC(0.95)优于单次测量(0.87)。

要点

  • sFlt-1/PlGF比值Z评分预测1周内并发症AUC为0.95,PlGF Z评分为0.94。
  • 血管生成失衡和/或蛋白尿者并发症率49.1%,阴性预测值92%。
  • 纵向测量比值变化的预测准确性优于单次测量(AUC 0.95 vs 0.87)。

核心结论

  • maternal血清血管生成标志物预测慢性高血压孕妇不良母胎结局优于临床评估。
  • 重复测量sFlt-1/PlGF比值较单次测量具有更好的预测准确性。

研究设计与样本

  • 纳入145例慢性高血压合并疑似子痫前期的孕妇。

主要发现

  • 26例(17.9%)在评估后1周内发生并发症,平均评估孕周29.9周。
  • 35例(24.1%)在任何时间发生并发症,平均评估孕周30.1周。
  • 发生并发症者sFlt-1/PlGF比值中位数149.4(IQR 64.6-457.4),未发生者为8.0(IQR 3.37-41.2),P<.001。
  • 预测1周内并发症的AUC:sFlt-1/PlGF比值Z评分0.95(95%CI 0.90-0.99),PlGF Z评分0.94(95%CI 0.88-0.99)。
  • 新发水肿AUC 0.61(95%CI 0.52-0.70)、蛋白尿0.62(95%CI 0.52-0.71)、平均动脉压升高0.52(95%CI 0.50-0.54)、其他子痫前期症状0.57(95%CI 0.49-0.65),均显著低于血管生成标志物(P<.001)。

临床怎么用

  • 对于慢性高血压合并疑似子痫前期的孕妇,可检测血清sFlt-1、PlGF及其比值以辅助预测不良母胎结局。
  • 建议重复测量sFlt-1/PlGF比值以动态评估风险,其预测准确性优于单次测量。
  • 血管生成标志物应纳入慢性高血压孕妇的临床管理指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women with chronic hypertension are at increased risk for adverse maternal and perinatal outcomes. Maternal serum angiogenic markers, such as soluble fms-like tyrosine kinase 1 and placental growth factor, can be used to triage women with suspected preeclampsia. However, data about these markers in pregnant women with chronic hypertension are scarce. OBJECTIVE: We aimed to evaluate the predictive accuracy of maternal serum levels of soluble fms-like tyrosine kinase 1, placental growth factor, and their ratio for predicting adverse maternal and perinatal outcomes in women with chronic hypertension. STUDY DESIGN: This was a retrospective analysis of prospectively collected data from January 2013 to October 2019 at the University of Vienna Hospital, Vienna, Austria. The inclusion criteria were pregnant women with chronic hypertension and suspected preeclampsia. The primary outcome of this study was the prognostic performance of angiogenic markers for the prediction of adverse maternal and perinatal outcomes in pregnant women with chronic hypertension. The accuracy of angiogenic markers for predicting adverse composite outcomes was assessed with a binomial logistic regression. The accuracy of each marker was assessed using receiver operating characteristics curves and area under the curve values. Area under the curve values were compared using De Long's test. RESULTS: Of the 145 included women with chronic hypertension and suspected superimposed preeclampsia, 26 (17.9%) women developed complications (ie, composite adverse maternal or fetal outcomes) within 1 week of assessment (average gestational age at assessment, 29.9 weeks) and 35 (24.1%) developed complications at any time (average gestational age at assessment, 30.1 weeks). In women who developed complications at any time, the median maternal serum soluble fms-like tyrosine kinase-1 to placental growth factor ratio was 149.4 (interquartile range, 64.6-457.4) compared with 8.0 (interquartile range, 3.37-41.2) for women who did not develop complications (P<.001). The area under the curve values for the maternal serum soluble fms-like tyrosine kinase-1 to placental growth factor ratio Z-score (0.95; 95% confidence interval, 0.90-0.99) and placental growth factor level Z-score (0.94; 95% confidence interval, 0.88-0.99) for predicting complications within 1 week of assessment were very high. The area under the curve values for new-onset edema (0.61; 95% confidence interval, 0.52-0.70), proteinuria (0.62; 95% confidence interval, 0.52-0.71), high mean arterial pressure (0.52; 95% confidence interval, 0.50-0.54), and other symptoms of preeclampsia (0.57; 95% confidence interval, 0.49-0.65) were all significantly lower than for the angiogenic markers (P<.001 for all). Women who had an angiogenic imbalance and/or proteinuria had the highest rate of complications (28/57, 49.1%). The rate of complications in women with an angiogenic imbalance and/or proteinuria was significantly higher than in women with either proteinuria, other symptoms, or intrauterine growth restriction in the absence of an angiogenic imbalance (49.1% vs 16.7%; P=.039). The highest positive and negative predictive values for predicting adverse outcomes were demonstrated by an angiogenic imbalance and/or proteinuria criteria with a positive predictive value of 49.1% (95% confidence interval, 50.4%-57.9%) and a negative predictive value of 92% (95% confidence interval, 85.5%-95.8%). Longitudinal changes in measurements of the gestational age-corrected ratio of soluble fms-like tyrosine kinase-1 to placental growth factor up to the last measurement had a significantly higher area under the curve value than the last measurement alone (area under the curve, 0.95; 95% confidence interval, 0.92-0.99 vs 0.87; 95% confidence interval, 0.79-0.95; P=.024) CONCLUSION: Maternal serum angiogenic markers are superior to clinical assessment in predicting adverse maternal and perinatal outcomes in pregnant women with chronic hypertension. Repeated measurements of the ratio of soluble fms-like tyrosine kinase-1 to placental growth factor seems beneficial given the better predictive accuracy compared with a single measurement alone. The use of angiogenic makers should be implemented in clinical management guidelines for pregnant women with chronic hypertension.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Binder J, Kalafat E, Palmrich P, et al. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension. Am J Obstet Gynecol. 2021. PMID: 33812812. doi:10.1016/j.ajog.2021.03.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。